NDATOPICALLOTION
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
ALTRENO (tretinoin) by Pfizer is nucleus. Approved for acne vulgaris, photoaging, melasma and 1 more indications. First approved in 2018.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALTRENO is a topical lotion formulation of tretinoin, a retinoid that activates retinoic acid nuclear receptors to modify gene expression and epithelial cell differentiation. It is FDA-approved for acne vulgaris and has broad off-label use across dermatology (photoaging, melasma, psoriasis) and oncology indications (acute promyelocytic leukemia, myelodysplastic syndromes, breast and prostate cancers). The mechanism reduces follicular epithelial cell cohesiveness, decreases microcomedo formation, and accelerates cell turnover.
$84KPart D
Peak12.3 years to LOEALTRENO remains in peak lifecycle phase with modest Medicare Part D uptake (880 claims in 2023), indicating a stable but niche commercial footprint relative to Pfizer's blockbuster portfolio.
Mechanism of Action
nucleus. Tretinoin activates three members of the retinoic acid (RAR) nuclear receptors (RARα, RARβ, and RARγ) which act to modify gene expression, subsequent protein synthesis, and epithelial cell growth and differentiation. It has not been established whether the clinical effects of tretinoin are…
Pharmacologic Class:
Retinoid
Indications (4)
Worked on ALTRENO at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.